Actively Recruiting

Phase 3
All Genders
Healthy Volunteers
NCT06526533

RECOMMEND Platform Trial

Led by Australian and New Zealand Intensive Care Research Centre · Updated on 2026-05-13

600

Participants Needed

3

Research Sites

166 weeks

Total Duration

On this page

Sponsors

A

Australian and New Zealand Intensive Care Research Centre

Lead Sponsor

M

Monash University

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this platform trial is to determine the efficacy, safety and cost-effectiveness of various interventions in patients with acute cardiorespiratory failure requiring extracorporeal membrane oxygenation (ECMO) The main question the platform trial aims to address is to determine the effect of a range of interventions on survival, organ support and resource utilisation to day 28 for hospitalised patients receiving ECMO. Researchers will compare various interventions within multiple platform trial domains to see if the interventions have effects on survival, organ support and resource utilisation for the patient cohort. Participants will be enrolled in accordance with the platform trial's domain structure to answer the research questions.

CONDITIONS

Official Title

RECOMMEND Platform Trial

Who Can Participate

All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients receiving ECMO
  • Patients enrolled in the EXCEL Registry - NCT03793257
  • Aged 18 years or older
Not Eligible

You will not qualify if you...

  • Treating clinician regards death as imminent and inevitable
  • Treating clinician determines it is not in the patient's best interests
  • Contraindication to RBC transfusion (including known patient preference)
  • Limitations of care put in place either through patient wishes or the treating medical teams
  • Participant has already received ECMO >12 hours
  • The treating physician anticipates that ECMO treatment will cease before the end of tomorrow
  • The treating physician deems the study is not in the patient's best interest
  • The treating physician has concern regarding patient ability to tolerate restrictive or liberal transfusion trigger thresholds
  • Actively listed for a solid organ transplant and has not yet received one
  • Suspected or confirmed to be pregnant
  • Previous ECMO treatment during the same hospital admission

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Royal Prince Alfred Hospital

Camperdown, New South Wales, Australia, 2050

Not Yet Recruiting

2

St. Vincent's Hospital Sydney

Sydney, New South Wales, Australia, 2010

Actively Recruiting

3

The Alfred Hospital

Melbourne, Victoria, Australia, 3004

Not Yet Recruiting

Loading map...

Research Team

C

Curtis Hopkins, B.BioMed, MPH, MHA

CONTACT

C

Carol Hodgson, PhD FACP FAHMS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here